

HANAI et al
Serial No. Unknown

2. **THEORETICAL CONSIDERATIONS**

REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,
NIXON & VANDERHYE P.C.
By: 
B. J. Sadoff
Reg. No. 36,663

BJS:Imy

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

HANAI et al
Serial No. Unknown

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) The derivative of an antibody according to claim 1 [or 2], wherein the monoclonal antibody comprises CDR1, CDR2 and CDR3 of H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

4. (Amended) The derivative of an antibody according to claim 1 [or 2], wherein the monoclonal antibody comprises CDR1, CDR2 and CDR3 of L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

5. (Amended) The derivative of an antibody according to claim 1 [or 2], wherein the monoclonal antibody comprises:

CDR1, CDR2 and CDR3 of a heavy chain (H chain) variable region (V region) having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively; and

CDR1, CDR2 and CDR3 of a light chain (L chain) V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

10. (Amended) The derivative of a human chimeric antibody according to claim 8 [or 9], wherein the H chain V region comprises the amino acid sequence represented by SEQ ID NO:55.

11. (Amended) The derivative of a human chimeric antibody according to claim 8 [or 9], wherein the L chain V region comprises the amino acid sequence represented by SEQ ID NO:56.

12. (Amended) The derivative of a human chimeric antibody according to claim 8 [or 9], wherein

the H chain V region comprises the amino acid sequence represented by SEQ ID NO:55; and

the L chain V region comprises the amino acid sequence represented by SEQ ID NO:56.

13. (Amended) The derivative of a human chimeric antibody KM871 according to claim 8 [or 9], wherein

the H chain V region comprises the amino acid sequence represented by SEQ ID NO:55; and

the L chain V region comprises the amino acid sequence represented by SEQ ID NO:56.

17. (Amended) The derivative of a human CDR-grafted antibody according to [any one of claims 14 to 16] claim 14, wherein the antibody comprises CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

HANAI et al
Serial No. Unknown

18. (Amended) The derivative of a human CDR-grafted antibody according to [any one of claims 14 to 16] claim 14, wherein the antibody comprises CDR1, CDR2 and CDR3 of the L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

19. (Amended) The derivative of a human CDR-grafted antibody according to [any one of claims 14 to 16] claim 14, wherein the antibody comprises:
CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively; and
CDR1, CDR2 and CDR3 of the L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

20. (Amended) The derivative of a human CDR-grafted antibody according to [any one of claims 14 to 16] claim 14, wherein the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9.

21. (Amended) The derivative of a human CDR-grafted antibody according to [any one of claims 14 to 16] claim 14, wherein the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

22. (Amended) The derivative of a human CDR-grafted antibody according to [any one of claims 14 to 16] claim 14, wherein the H chain V region and the L chain V

region of the antibody comprises the amino acid sequences represented by SEQ ID NO:9 and SEQ ID NO:54, respectively.

23. (Amended) The derivative of a human CDR-grafted antibody KM8871 according to [any one of claims 14 to 16] claim 14, wherein

the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9; and

the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

25. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises amino acid sequences of an H chain V region and an L chain V region of a monoclonal antibody against ganglioside GD3 produced by a hybridoma.

26. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:55.

27. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:56.

28. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises:

an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:55; and

an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:56.

29. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises amino acid sequences of an H chain V region and an L chain V region of a human CDR-grafted antibody against ganglioside GD3.

30. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:9.

31. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:54.

32. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises:

HANAI et al
Serial No. Unknown

an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:9; and

an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:54.

33. (Amended) The derivative of an antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises CDR1, CDR2 and CDR3 of an H chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

34. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises CDR1, CDR2 and CDR3 of an L chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

35. (Amended) The derivative of the antibody fragment according to claim 1 [or 24], wherein the antibody fragment comprises:

CDR1, CDR2 and CDR3 of an H chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5; and

CDR1, CDR2 and CDR3 of an L chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8.

36. (Amended) The derivative of a monoclonal antibody or the antibody fragment thereof according to [any one of claim 1 to 35] claim 1, wherein the protein is a cytokine.

42. (Amended) A DNA which encodes the derivative of a monoclonal antibody or the derivative of the antibody fragment thereof which specifically reacts with ganglioside GD3 according to [any one of claims 1 to 41] claim 1.

47. (Amended) A process for producing an antibody, which comprises: culturing the transformant according to [any one of claims 44 to 46] claim 44 in a culture medium to produce and accumulate the derivative of a monoclonal antibody or the derivative of the antibody fragment thereof [according to any one of claims 1 to 41] in the culture; and

recovering the derivative of the antibody or the derivative of the antibody fragment thereof from the culture.

52. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to [any one of claims 49 to 51] claim 49, wherein the antibody comprises CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

53. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to [any one of claims 49 to 51] claim 49, wherein the antibody

comprises CDR1, CDR2 and CDR3 of the L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

54. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to [any one of claims 49 to 51] claim 49, wherein the antibody comprises:

CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively; and

CDR1, CDR2 and CDR3 of the L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8.

55. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to [any one of claims 49 to 51] claim 49, wherein the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9.

56. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to [any one of claims 49 to 51] claim 49, wherein the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

57. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to [any one of claims 49 to 51] claim 49, wherein the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9; and

HANAI et al
Serial No. Unknown

the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

58. (Amended) The human CDR-grafted antibody KM8871 or the antibody fragment thereof according to [any one of claims 49 to 51] claim 49, wherein the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9; and the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

59. (Amended) A DNA which encodes the human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with ganglioside GD3 according to [any one of claims 48 to 58] claim 48.

63. (Amended) A process for producing an antibody, which comprises:
culturing the transformant according to claim 61 [or 62] in a culture medium to
produce and accumulate the human CDR-grafted antibody or the antibody fragment
thereof [according to any one of claims 48 to 58] in the culture; and
recovering the antibody or the antibody fragment thereof from the culture.

64. (Amended) A medicament comprising at least one selected from the derivative of a monoclonal antibody and the derivative of the antibody fragment thereof according to [claims 1 to 41] claim 1 and the human CDR-grafted antibody and the

HANAI et al
Serial No. Unknown

antibody fragment thereof [according to any one of claims 48 to 58] which specifically reacts with ganglioside GD3.

65. (Amended) A therapeutic agent for cancers, comprising, as an active ingredient, at least one selected from the derivative of a monoclonal antibody and the derivative of the antibody fragment thereof according to [any one of claims 1 to 41] claim 1 and the human CDR-grafted antibody and the antibody fragment thereof [according to any one of claims 48 to 58] which specifically reacts with ganglioside GD3.

66. (Amended) A diagnostic agent for cancers, comprising, as an active ingredient, at least one selected from the derivative of a monoclonal antibody and the derivative of the antibody fragment thereof according to [any one of claims 1 to 41] claim 1 and the human CDR-grafted antibody and the antibody fragment thereof [according to any one of claims 48 to 58] which specifically reacts with ganglioside GD3.